Programmaschema Chicago op Schier 2023 – maandag 4 juni

Maandag 5 juni 2023

08.30 uur Virtual ASCO – Locatie: Dorpshuis

Educational The early stage triple negative breast cancer journey: Beginning, end and everything in between.

P. Vikas Management of Immunotoxicities in the Short and Long Term.

Educational Managing a long and winding road: ER-positive breast cancer

M. Gnant Late Recurrences in ER-Positive Breast Cancer: What Else Can We Do?

Oral abstract session breast cancer adjuvant (80 min.)

R. Gray – Effects of ovarian ablation or suppression on breast cancer recurrence and survival: Patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials. Abs# 503
I. Luis – Thinking Differently About Breast Cancer in Young Women.
Cortes – 3-year invasive disease-free survival (iDFS) of the strategy-based, randomized phase II PHERGain trial evaluating chemotherapy (CT) de-escalation in human epidermal growth factor receptor 2-positive (HER2[+]) early breast cancer (EBC) Abs# LBA506
J. Balko Should Biomarkers Guide Therapy for Early-Stage Breast Cancer?

Rapid Abstract session

P. Conte – Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial. Abs# LBA637
I. Graetz – A randomized controlled trial of a mobile app and tailored messages to improve outcomes among women with breast cancer receiving adjuvant endocrine therapy. Abs# 512

10.20 uur Pauze

10.30-12.00 uur Virtual ASCO – Locatie: Dorpshuis

Educational: Next generation approaches to immune-oncology in gastrointestinal cancers: Beyond checkpoint inhibitors

M. Morelli Current Immuno-oncology Approaches and the Future for New Combinations in Gastrointestinal Cancers

Educational Colorectaal: Minimizing toxicity in the neo-adjuvant treatment of rectal cancer

Ciombor Neoadjuvant Immunotherapy in MSI-High Rectal Cancer
Sanford Evolving Role of Radiation in Rectal Cancer: Optimizing a Crucial Tool
Guillem Watching or Waiting After Complete Response to Total Neoadjuvant Therapy: No Doubt About It

Shrag PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048) Abs# LBA2

Corrie Marijnen Discussant abs# LBA2

12.00 uur Einde ochtendprogramma

Fietsen ophalen, Badweg 6
Lunch, Strandpaviljoen De Marlijn, Prins Bernhardweg 2

14.00 uur Virtual ASCO, locatie: Dorpshuis

Educational colorectal: Emerging therapies for colorectal cancer

  • C. Wu Molecular Targets in Colorectal Cancer: Moving Beyond EGFR, BRAF, and dMMR
  • O. Alese Targeting DNA Repair Abnormalities in Microsatellite Stable Colorectal Cancer: An Effective Strategy?

Oral abstract session GE Colorectaal

  • Antoniotti FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study Abs#3500
  • Raghav Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC): Primary results from the multicenter, randomized, phase 2 DESTINY-CRC02 study Abs#3501
  • Bekaii-Saab TRIBE Meets DESTINY: A LEAP Forward in the Treatment of Advanced Colorectal Cancer Abstract discussant

15.10-15.30 Pauze

  • Jensen Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial Abs#LBA3503
  • Conroy Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: 7-year results of PRODIGE 23 phase III trial, a UNICANCER GI trial Abs#LBA3504
  • Deng Long-term outcome of neoadjuvant mFOLFOX6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: A multicenter, randomized phase III trial Abs#3505
  • You Neoadjuvant Treatment Strategies in Colon and Rectal Cancers: What Is the Worth Abstracts Discussant

16.30 uur Live verbinding met Chicago: Jeanine Roodhart

17.30 uur Pauze + teruglopen naar Van der Werff

17.45 uur Klinische implicaties olv referent (besloten) – Locatie: Van der Werff

18.45 uur Einde middagprogramma

19.30 uur Diner in restaurant Van der Werff

Woensdag 7 juni 2023
Dinsdag 6 juni 2023
Zondag 4 juni 2023

© Copyright 2023 - Congress Care - Website door Lemone